EUVIMEDEUVIMED entdecken
ÄquivalenzstudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Comparing letrozole and mifepristone pre‐treatment in medical management of first trimester missed miscarriage: a prospective open‐label non‐inferiority randomised controlled trial

Libei Du iD, Hang Wun Raymond Li iD, Kristina Gemzell-Danielsson iD, Zhiqiang Zhang, Yanhong Du, Wenju Zhang, Bo Xu, Xiaozhong Wang, Yaokai Wang, Wenjuan Wan, Ying Chang, Weiyu Diao und 3 weitere

BJOG: An International Journal of Obstetrics & Gynaecology · 2024

DOI: 10.1111/1471-0528.17646 ↗

Kurz gefasst

Äquivalenzstudie in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2024. Verfasst von Libei Du und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, The University of Hong Kong - Shenzhen Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Abortifacient Agents, Nonsteroidal, Abortion, Incomplete, Abortion, Induced, Misoprostol. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate whether letrozole pre‐treatment is non‐inferior to mifepristone pre‐treatment, followed by misoprostol, for complete evacuation in the medical treatment of first‐trimester missed miscarriage.

Design

Prospective open‐label non‐inferiority randomised controlled trial.

Setting

A university‐affiliated hospital. Population We recruited 294 women diagnosed with first‐trimester missed miscarriage who opted for medical treatment.

Methods

Participants were randomly assigned to: (i) the mifepristone group, who received 200 mg mifepristone orally followed 24–48 h later by 800 μg misoprostol vaginally; or (ii) the letrozole group, who received 10 mg letrozole orally once‐a‐day for 3 days, followed by 800 μg misoprostol vaginally on the third (i.e. last) day of letrozole administration. Main outcome measures The primary outcome was the rate of complete evacuation without surgical intervention at 42 days post‐treatment. Secondary outcomes included induction‐to‐expulsion interval, adverse effects, women's satisfaction, number of doses of misoprostol required, duration of vaginal bleeding, pain score on the day of misoprostol administration and other adverse events.

Results

The complete evacuation rates were 97.8% (95% CI 95.1%–100%) and 97.2% (95% CI 94.4%–99.9%) in the letrozole and mifepristone groups, respectively ( p ≤ 0.001 for non‐inferiority). The mean induction‐to‐tissue expulsion interval in the letrozole group was longer compared with the mifepristone group (15.4 vs 9.0 h) ( p = 0.03). The letrozole group had less heavy post‐treatment bleeding and an earlier return of menses. There were no statistically significant differences in the number of doses of misoprostol required, the duration of vaginal bleeding, the pain score on the day of misoprostol administration and the rate of other adverse events between the two groups. The majority of the women (91.2% and 93.9% in the letrozole and mifepristone groups, respectively) were satisfied with their treatment option.

Conclusions

Letrozole is non‐inferior to mifepristone as a pre‐treatment, followed by misoprostol, for the medical treatment of first‐trimester missed miscarriage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Abortifacient Agents, NonsteroidalAbortion, IncompleteAbortion, InducedMisoprostolFemaleHumansPregnancyLetrozoleMifepristonePainPregnancy Trimester, FirstProspective StudiesTreatment OutcomeUterine Hemorrhage

Stichwörter der Autor:innen

letrozolemedical treatmentmifepristonemissed miscarriagenon-inferiority randomised trial

Substanzen

Abortifacient Agents, NonsteroidalLetrozoleMifepristoneMisoprostol

Autor:innen und Institutionen

  • Department of Obstetrics and Gynaecology, The University of Hong Kong - Shenzhen Hospital, Shenzhen, China.
  • Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong Special Administrative Region, China.
  • Department of Women's and Children's Health, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
  • Department of Statistics and Actuarial Science, The University of Hong Kong, Hong Kong Special Administrative Region, China.

ORCID-Profile: Libei Du, Hang Wun Raymond Li, Kristina Gemzell-Danielsson, Pak Chung Ho

Zitieren

APA

Du, L., Li, H. W. R., Gemzell-Danielsson, K., Zhang, Z., Du, Y., Zhang, W., Xu, B., Wang, X., Wang, Y., Wan, W., Chang, Y., Diao, W., Wang, Y., Zhang, L., & Ho, P. C. (2024). Comparing letrozole and mifepristone pre‐treatment in medical management of first trimester missed miscarriage: a prospective open‐label non‐inferiority randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17646

Vancouver

Du L, Li HWR, Gemzell-Danielsson K, Zhang Z, Du Y, Zhang W, et al. Comparing letrozole and mifepristone pre‐treatment in medical management of first trimester missed miscarriage: a prospective open‐label non‐inferiority randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2024. doi:10.1111/1471-0528.17646

BibTeX
@article{Du2024,
  author = {Du, Libei and Li, Hang Wun Raymond and Gemzell-Danielsson, Kristina and Zhang, Zhiqiang and Du, Yanhong and Zhang, Wenju and Xu, Bo and Wang, Xiaozhong and Wang, Yaokai and Wan, Wenjuan and Chang, Ying and Diao, Weiyu and Wang, Yanli and Zhang, Li and Ho, Pak Chung},
  title = {Comparing letrozole and mifepristone pre‐treatment in medical management of first trimester missed miscarriage: a prospective open‐label non‐inferiority randomised controlled trial},
  journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
  year = {2024},
  doi = {10.1111/1471-0528.17646}
}
Kostenlos starten →